NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight [Yahoo! Finance]
NervGen Pharma FY GAAP EPS of -$0.61 [Seeking Alpha]
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]